Our data suggest that the upregulation of miR‐3133 can downregulate these target genes and lead to the inactivation of YAP and decreased ubiquitination‐mediated p53 degradation, thus changing the expression of downstream target genes and reducing the proliferation and drug resistance of tumour cells. The gene discussed is TP53; the disease is neoplasm.